These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34028789)

  • 1. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab.
    Simpson K; Dolianitis C
    Australas J Dermatol; 2021 Aug; 62(3):441-442. PubMed ID: 34028789
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.
    Cole D; Mohammad T; Lim H
    Br J Dermatol; 2019 Dec; 181(6):1331-1332. PubMed ID: 31260082
    [No Abstract]   [Full Text] [Related]  

  • 3. Pityriasis rubra pilaris with polyarthritis treated with adalimumab.
    Chiu HY; Tsai TF
    J Am Acad Dermatol; 2013 Jan; 68(1):187-8. PubMed ID: 23244382
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab.
    Villa-Gonzalez JM; Gonzalez-Hermosa MR; Atxutegi-Ayesta X; Ratón Nieto JA; Gardeazabal García J; Lasa Elgezua O
    Clin Exp Dermatol; 2024 Jan; 49(2):177-180. PubMed ID: 37847660
    [No Abstract]   [Full Text] [Related]  

  • 5. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris.
    Papini M; Russo A; Natalini Y; Troiani L; Cassiani L
    Ital J Dermatol Venerol; 2021 Aug; 156(4):501-502. PubMed ID: 33179881
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of Pityriasis rubra pilaris with brodalumab.
    De Rosa A; Gambardella A; Licata G; Alfano R; Argenziano G
    Australas J Dermatol; 2020 May; 61(2):e249-e251. PubMed ID: 31851372
    [No Abstract]   [Full Text] [Related]  

  • 7. Refractory Type I pityriasis rubra pilaris treated with tildrakizumab.
    Licata G; Gambardella A; Calabrese G; Pagliuca F; Alfano R; Argenziano G
    Clin Exp Dermatol; 2021 Dec; 46(8):1594-1595. PubMed ID: 34101231
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Pityriasis Rubra Pilaris With Guselkumab.
    Pilz AC; Seiringer P; Biedermann T; Eyerich K
    JAMA Dermatol; 2019 Dec; 155(12):1424-1426. PubMed ID: 31577328
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy.
    Xu YH; Dong DD; Lin YF; Wang Q; Huang LM; Shi JQ
    Clin Exp Dermatol; 2022 Nov; 47(11):2043-2045. PubMed ID: 35906074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of pityriasis rubra pilaris with tildrakizumab.
    Zagarella SS; Jiang KW
    Australas J Dermatol; 2022 Feb; 63(1):120-121. PubMed ID: 34854479
    [No Abstract]   [Full Text] [Related]  

  • 11. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.
    Chastagner M; Hoelt P; Kanitakis J; Jullien D; Villani AP
    Eur J Dermatol; 2019 Apr; 29(2):218-220. PubMed ID: 30827945
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pityriasis rubra pilaris : Successful treatment with ixekizumab].
    Kohn D; Wetzig T
    Hautarzt; 2020 Aug; 71(8):624-626. PubMed ID: 32185430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.
    Liang JY; Ye RX; Tian X; Zhang SQ; Zhang XB
    Dermatol Ther; 2020 Nov; 33(6):e14097. PubMed ID: 32725719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of pityriasis rubra pilaris with adalimumab - case report.
    Bravo EA; Carrion L; Paucar SM; Mendoza R; Rivera C
    Dermatol Online J; 2014 Apr; 20(4):22374. PubMed ID: 24746310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for the treatment of pityriasis rubra pilaris: a case report.
    Wassef C; Lombardi A; Rao BK
    Cutis; 2012 Nov; 90(5):244-7. PubMed ID: 23270195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab in refractory pityriasis rubra pilaris.
    Kromer C; Schön MP; Mössner R
    J Dtsch Dermatol Ges; 2024 Jan; 22(1):102-104. PubMed ID: 38066410
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of pityriasis rubra pilaris with guselkumab: Serum CCL20 as a potential marker for the disease activity.
    Nagai H; Jimbo H; Matsuura S; Tatsuoka S; Shiraki E; Nishigori C
    Dermatol Ther; 2020 Nov; 33(6):e14403. PubMed ID: 33044038
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14.
    Eytan O; Sarig O; Sprecher E; van Steensel MA
    Br J Dermatol; 2014 Aug; 171(2):420-2. PubMed ID: 24641799
    [No Abstract]   [Full Text] [Related]  

  • 20. [CD30-positive anaplastic large cell T-cell lymphoma developing during immunosuppressive therapy of pityriasis rubra pilaris with ustekinumab].
    Humme D; Beyer M; Röwert-Huber HJ; Sterry W; Philipp S
    Hautarzt; 2013 Mar; 64(3):190-4. PubMed ID: 23322178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.